» Articles » PMID: 29445239

The Urokinase Receptor Induces a Mesenchymal Gene Expression Signature in Glioblastoma Cells and Promotes Tumor Cell Survival in Neurospheres

Overview
Journal Sci Rep
Specialty Science
Date 2018 Feb 16
PMID 29445239
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

PLAUR encodes the urokinase receptor (uPAR), which promotes cell survival, migration, and resistance to targeted cancer therapeutics in glioblastoma cells in culture and in mouse model systems. Herein, we show that patient survival correlates inversely with PLAUR mRNA expression in gliomas of all grades, in glioblastomas, and in the subset of glioblastomas that demonstrate the mesenchymal gene expression signature. PLAUR clusters with genes that define the more aggressive mesenchymal subtype in transcriptome profiles of glioblastoma tissue and glioblastoma cells in neurospheres, which are enriched for multipotent cells with stem cell-like qualities. When PLAUR was over-expressed or silenced in glioblastoma cells, neurosphere growth and expression of mesenchymal subtype biomarkers correlated with uPAR abundance. uPAR also promoted glioblastoma cell survival in neurospheres. Constitutively-active EGF Receptor (EGFRvIII) promoted neurosphere growth; however, unlike uPAR, EGFRvIII did not induce the mesenchymal gene expression signature. Immunohistochemical analysis of human glioblastomas showed that uPAR is typically expressed by a small sub-population of the cancer cells; it is thus reasonable to conclude that this subpopulation of cells is responsible for the effects of PLAUR on patient survival. We propose that uPAR-expressing glioblastoma cells demonstrate a mesenchymal gene signature, an increased capacity for cell survival, and stem cell-like properties.

Citing Articles

CTHRC1 fibroblasts and SPP1 macrophages synergistically contribute to pro-tumorigenic tumor microenvironment in pancreatic ductal adenocarcinoma.

Li E, Cheung H, Ma S Sci Rep. 2024; 14(1):17412.

PMID: 39075108 PMC: 11286765. DOI: 10.1038/s41598-024-68109-z.


mRNA markers for survival prediction in glioblastoma multiforme patients: a systematic review with bioinformatic analyses.

Azimi P, Yazdanian T, Ahmadiani A BMC Cancer. 2024; 24(1):612.

PMID: 38773447 PMC: 11106946. DOI: 10.1186/s12885-024-12345-z.


Identifying PLAUR as a Pivotal Gene of Tumor Microenvironment and Regulating Mesenchymal Phenotype of Glioblastoma.

Fu Z, Chen Z, Ye J, Ji J, Ni W, Lin W Cancers (Basel). 2024; 16(4).

PMID: 38398231 PMC: 10887327. DOI: 10.3390/cancers16040840.


uPAR (PLAUR) Marks Two Intra-Tumoral Subtypes of Glioblastoma: Insights from Single-Cell RNA Sequencing.

He Y, Dossing K, Rossing M, Bagger F, Kjaer A Int J Mol Sci. 2024; 25(4).

PMID: 38396677 PMC: 10889167. DOI: 10.3390/ijms25041998.


Diversity and heterogeneity in human breast cancer adipose tissue revealed at single-nucleus resolution.

Tang L, Li T, Xie J, Huo Y Front Immunol. 2023; 14:1158027.

PMID: 37153595 PMC: 10160491. DOI: 10.3389/fimmu.2023.1158027.


References
1.
Gilder A, Wang L, Natali L, Karimi-Mostowfi N, Brifault C, Gonias S . Pertussis Toxin Is a Robust and Selective Inhibitor of High Grade Glioma Cell Migration and Invasion. PLoS One. 2016; 11(12):e0168418. PMC: 5158192. DOI: 10.1371/journal.pone.0168418. View

2.
Chen R, Nishimura M, Bumbaca S, Kharbanda S, Forrest W, Kasman I . A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell. 2010; 17(4):362-75. DOI: 10.1016/j.ccr.2009.12.049. View

3.
Wang Z, Gerstein M, Snyder M . RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2008; 10(1):57-63. PMC: 2949280. DOI: 10.1038/nrg2484. View

4.
Solberg H, Ploug M, Hoyer-Hansen G, Nielsen B, Lund L . The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J Histochem Cytochem. 2001; 49(2):237-46. DOI: 10.1177/002215540104900211. View

5.
Singh A, Settleman J . EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29(34):4741-51. PMC: 3176718. DOI: 10.1038/onc.2010.215. View